Vikas Lifecare Reports Q3 Loss Amid Shareholder Vote on Key Deals

Vikas Lifecare Limited's Board of Directors met on April 21, 2026, to approve unaudited financial results for the periods ending September 30, 2025, and December 31, 2025. The company reported a standalone loss before tax of ₹18.76 lakh for the quarter ended December 31, 2025, on revenue of ₹96.54 lakh. This marks a change from the ₹104.39 lakh profit before tax recorded for the nine months ending December 31, 2025. The board also decided to seek shareholder consent via postal ballot for several essential business transactions, including investments, loans, and guarantees.

Company Performance and Shareholder Approval

These financial results offer shareholders current performance data. The need to secure shareholder consent for various business transactions via postal ballot highlights the company's operational requirements and strategic path. Vikas Lifecare is also navigating regulatory compliance for cross-border dealings concerning Ebix Inc. and IGL Genesis Technologies, signifying complex ongoing deal structures. Shareholder approval is vital for these transactions to proceed, enabling efficient operations and supporting the company's active work on conditions precedent and regulatory checks for its Ebix Inc. settlement and the IGL Genesis Technologies investment.

Company Background and Key Ventures

Vikas Lifecare operates a diversified business across polymers, specialty chemicals, FMCG, agro, and smart gas meters. Previously, the company committed USD 34.8 million to a consortium for the acquisition of Ebix Inc., later securing an arbitration award in July 2025 related to this investment. Separately, a joint venture named IGL Genesis Technologies was established with Indraprastha Gas Ltd. for smart gas meter manufacturing, although the transfer of investment in this venture awaits approvals. The company has also outlined fundraising plans, including a ₹200 crore preferential issue.

Key Risks and Shareholder Votes

Investors are watching several key areas. An income tax demand of ₹22.99 crore has been issued, against which Vikas Lifecare intends to file an appeal. The planned transfer of investment in IGL Genesis Technologies Limited still requires pending approvals from Indraprastha Gas Limited and the IGTL Board. Furthermore, shareholder approval is pending for material related party transactions that occurred during the first half of FY26.

Industry Peers

Operating across diverse sectors, Vikas Lifecare's peers include companies with varied interests like Adani Enterprises Ltd. and MMTC Ltd. Dhampur Bio Organics Ltd. is noted for its operations in related chemical and agricultural segments, providing benchmarks for growth strategies.

Financial Snapshot

As of September 30, 2025, the company reported consolidated total assets of ₹73,128.45 million and consolidated total equity of ₹55,396.12 million.

Looking Ahead

Investors will be monitoring the outcomes of the shareholder approval process for business transactions via postal ballot. Key developments also include the resolution of pending conditions and approvals for the IGL Genesis Technologies Limited investment, and the finalization of tax implications concerning the Ebix Inc. settlement.